Watch out for long position in GenmabGenmab has reached an important area, which before in time have been a good time to start a long postion.
67DKK
4.35 BDKK
16.47 BDKK
63.70 M
About GENMAB A/S
Sector
CEO
Jan G. J. van de Winkel
Headquarters
Copenhagen
Website
Employees (FY)
2.2 K
Founded
1998
ISIN
DK0010272202
FIGI
BBG000BKPC99
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Genmap Correction -40 %I like Genmab. The stock was one of my long positions for many years. I went into cash in the fall of 2021. After minus 40 percent, I will now gradually add to Genmab again.
Genmab is a era done ?I have sold all of my genmab shares i started to buy at the start of corona, 5 year tmeframe i think we see a head an shoulder formation an hoping to buy again 15-1600 kr :)
in the stockHello again, i bought this stock last year at like 1500 kr, but unf. i see a Head an should forming in think it will fall a little back, of course i hope im wrong an go up from here :) An not selling holding at least 5-20 years :)
Inverse Cup and handle on the weekly $GMABInverse Cup and handle on the weekly $GMAB
- Inverse Cup and handle on the weekly
- VPVR acting as resistance
- Waiting for a trigger
Interesting cup with handle developmentLooks like we have a cup with handle. Potential target 3600-3800
Genmab opportunitysteamloss in the Genmab stock will likely fuel a new rush.
1) the 2 previous times times RSI has been below 30, it has resulted in strong returns. Will it happen a 3rd time?
2) The current strongly rising RSI will like make sure that the price will move and stay above the short term downward trend
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where GMAB is featured.
Frequently Asked Questions
The current price of GMAB is 2007.00 DKK — it has decreased by 2.48% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXCOP exchange GENMAB A/S stocks are traded under the ticker GMAB.
GENMAB A/S is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for GENMAB A/S has a max estimate of 3436.33 DKK and a min estimate of 1860.00 DKK.
GMAB earnings for the last quarter are 32.32 DKK whereas the estimation was 22.87 DKK which accounts for 41.35% surprise. Estimated earnings for the next quarter are 21.52 DKK. See more details about GENMAB A/S earnings.
GENMAB A/S revenue for the last quarter amounts to 4.74 B DKK despite the estimated figure of 4.49 B DKK. In the next quarter revenue is expected to reach 4.61 B DKK.
Yes, you can track GENMAB A/S financials in yearly and quarterly reports right on TradingView.
Like other stocks, GMAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENMAB A/S stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 2.20 K employees. See our rating of the largest employees — is GENMAB A/S on this list?